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ABSTRACT  
Health is a fully individualized concern, and is therefore inherently mobile. Thus, Ubiquitous Healthcare 
Information Systems can enable a much-needed patient-centered care environment. This paper presents a decision 
support system that makes use of system dynamics methodologies in order to assess the improved health benefits 
that may be realized within the context of ubiquitous healthcare information systems in support of managing 
diabetes.   
Keywords  
Ubiquitous Healthcare Information System, pervasive technology, System Dynamics, DSS, patient-centered care, 
health benefits 
INTRODUCTION 
Ubiquitous Healthcare Information Systems (UHIS), in which pervasive and ubiquitous consumer technologies 
interoperate with healthcare providers’ information systems to monitor and exchange patient medical information, 
have three primary objectives: to reduce time loss due to lag, to reduce inaccuracies in traditional medical 
information flows, and to reduce the costs of information flow (Joo-hak, 2008). Lag refers to the time required for 
acquiring information from paper-based systems or personal contact, for example, in order to inform treatment plan 
decisions. A reduction in lag can reduce the gap between when data is recorded and when that information is 
available for processing in support of treatment plan decisions. To assess the benefits over time of UHIS in support 
of managing a chronic medical condition such as diabetes, we present a decision support system that makes use of 
system dynamics modeling techniques.  
UHIS are advocated to support patients’ compliance with commonly accepted care plans, and to help detect patients’ 
medical conditions in real time, thereby improving diagnoses (Dishman, 2004). They take on a range of forms, from 
pervasive and ubiquitous technologies such Internet access, mobile phones and PDAs, to specialized technologies 
that are worn by or embedded in patients and become an unobtrusive part of patients’ daily lives (ibid.; Korhonen 
and Bardram, 2004). Examples of current and future UHIS abound. Scholars contend, for example, that patients can 
benefit from participating in online health communities  (e.g., Johnson and Ambrose, 2006). Through social 
interaction with others that have experienced similar medical conditions, patients may receive affective and social 
support, and opportunities to discuss and enhance their comprehension of healthcare providers’ advice and 
diagnoses. Consequently, online health communities may lead to improved compliance with commonly accepted 
care plans. Internet applications such as Microsoft HealthVault and Google Health also enable patients to record 
information about their medical indications (e.g., weight and blood pressure) over time and aggregate data from 
healthcare providers in order to provide up-to-date information to doctors, specialists, emergency and other 
healthcare personnel (Steinbrook, 2008), in support of diagnosis and treatment. PDAs (personal digital assistants) 
and mobile phones offer a mobile platform for logging biological information (e.g., blood glucose, pressure) and 
subsequently providing real-time guidance to the patient in support of compliance (e.g., alerting the patient that 
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he/she needs more exercise) and/or submitting the information wirelessly to healthcare providers in support of 
diagnoses and adjustments to care plans (Korhonen and Bardram, 2004). Pundits also tout specialized technologies 
in the near future that are worn by or embedded in patients and that automatically monitor and log biological 
information to mobile phones or PDAs (Bonato, 2003) in support of diagnosis and care decisions. Specialized 
technologies ready for commercialization include wearable clothing, rings and sensors embedded in the bloodstream 
that can automatically monitor activity levels, blood pressure, and signs of seizures and cardiovascular events, for 
example, that signal and inform medical intervention to preempt serious medical complications. Researchers are also 
developing data mining techniques to analyze the copious amounts of data made available by UHIS, in order to 
identify meaningful information in support of actors’ care plan decisions and diagnoses. 
To highlight the significance of information flow among actors in support of diabetes management, Montazemi et 
al. (2009) applied a dependency network diagram (DND) analysis within the context of diabetes management in 
Canada. They find that although patients are well supported by personal communications with healthcare providers, 
at present patients are disenfranchised from information flows in healthcare providers’ information systems and the 
potential of that information to support patients’ participation in care decisions and self-care. Although DND 
provides a good representation of information dependencies among the actors, it doesn’t allow decision makers (i.e., 
policymakers) to assess the effects of a future UHIS. Therefore, the aim of this research is to present a decision 
support system (DSS) model to assess the possible benefits of using UHIS to diagnose medical conditions early and 
to support compliance with commonly accepted care plans.  
The benefits of UHIS can be measured in the form of resulting improved operational efficiency and improved 
effectiveness in decision processes. Our focus in this paper is on the possible improved effectiveness of decision 
processes that would result in improved patient health status. Thus, the research question in this paper is ‘How could 
we assess the possible effectiveness of ubiquitous healthcare information systems on patients’ health status over 
time?’ Our basic assumption is that UHIS would improve decision processes that result in improved diagnosis and 
improved control rates of patients’ conditions and risk factors, in compliance with commonly accepted care plans. 
To this end, we propose a DSS that makes use of systems dynamics methodologies to simulate the possible 
improved effectiveness of UHIS on diabetes-related health status. 
BACKGROUND 
The context of managing diabetes in Canadian healthcare systems provides a poignant example of patient-centered 
care that relies on information exchange among patients and numerous healthcare providers in care management 
decisions. Scholars find that patients’ active participation in diabetes management decisions can substantially 
mitigate the escalation of medical complications and associated treatment costs (Homer et al., 2004a; Testa and 
Simonson, 1998; Wagner et al., 2001) – costs that amounted to CAD$6 billion of the $54 billion Canada’s provinces 
and territories spent on public healthcare in 2000 (PTMH, 2000). To that end, more than a decade of medical 
literature has advocated the redesign of chronic care management, such as diabetes, to a “patient-centered care” 
model (e.g., Von Korff et al., 1997; Wagner et al., 1996) characterized by the exchange of all information relevant 
to decision-making between patients and healthcare providers (Bugge et al., 2006). The redesign involves moving 
beyond a care model designed around providers managing illnesses, to a model designed around patients and 
providers proactively managing patients’ self-care (Dishman, 2004; Korhonen and Bardram, 2004). In the redesign, 
information and communication technologies can play a major role by helping to “detect disease early and support 
compliance with commonly accepted care plans” (Dishman, 2004, p. 35). In particular, pervasive consumer 
technologies interoperating with healthcare providers’ information systems (i.e., UHIS) can enable real-time 
information exchange in support of prevention, diagnosis, and treatment. Prevention, diagnosis and treatment are 
important factors in the escalation of diabetes over time. 
Diabetes mellitus is a chronic condition that tends to escalate throughout patients’ life cycles (see Figure 1), 
especially if left undetected and uncontrolled (D’Cruz, 2008). The normoglycemic population refers to individuals 
whose blood glucose levels remain within a commonly accepted range. The pre-diabetic stage refers to individuals 
who have amplified risk factors for diabetes, such as obesity and aging, and whose blood glucose levels hover 
around the upper level of the commonly accepted normoglycemic range. In the third stage, the individual is 
diagnosed with diabetes. Their blood glucose levels frequently exceed the normoglycemic range, which amplifies 
their risk of experiencing fourth-stage medical complications such as stroke, heart attack, vision problems and foot 
disorders (O’Reilly et al., 2007). Therefore, patients’ health status deteriorates with the escalation of diabetes, and 
the overarching objective of diabetes health care is to mitigate escalation. Escalation can be substantially mitigated 
provided that risk factors and medical conditions are accurately diagnosed (i.e., detected), and the patient complies 
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with medical best practices in prevention, monitoring and control of their risk factors (e.g., through diet and 
exercise) and medical conditions (e.g., monitoring blood glucose, administering insulin) (ADA, 2003; Testa and 
Simonson, 1998; Wagner et al., 2001). Management of diabetes is necessarily patient-centered because substantial 
segments of the management – diet, exercise, self-monitoring and medication use, for example – rely on the actions 
of patients over their life cycles (Bodenheimer et al., 2002; Wagner et al., 1996). However, numerous healthcare 
providers with specialized knowledge play a role in informing treatment plan decisions. 
 
Figure 1. Conceptual illustration of the escalation of diabetes through patients’ life cycles 
 
THEORETICAL FOUNDATION 
Actors involved in patient-centered care (i.e., patients, physicians, nurses, dieticians, medical laboratory technicians, 
pharmacists) apply their knowledge to acquire and share information relevant to coordinated treatment plans for a 
specific patient. Within this context, actors communicate with each other to reduce uncertainty, thereby making their 
decision environments more predictable (Te'eni, 2001). Communication among networked actors supplements 
information exchange by providing opportunities for clarification and sense-making regarding the potential impacts 
of alternative treatment strategies for a specific patient (Grabowski and Roberts, 1999). DND methodology affords a 
means to identify dependencies among the actors to get a sense of information flow among the actors. In accordance 
with the DND methodology (Tillquist et al., 2002), Montazemi et al. (2009) identified distinct goals of actors that 
are expected to cumulate in the achievement of the overarching objective (i.e., to manage patients’ diabetic risks and 
conditions in order to mitigate escalation of medical complications over time). To accomplish each goal, actors must 
complete specific actions. They found that patients cannot complete the necessary actions without relying on 
information from multiple healthcare providers. Specifically, patients have information dependencies on multiple 
healthcare providers. In turn, healthcare providers take on care delivery goals and undertake actions that contribute 
to treatment plan decisions and implementation, which generates further information dependencies between 
healthcare providers in support of care delivery. Coordination refers to how actors interact and exchange 
information (i.e., communicate) to satisfy their dependencies, and thereby form ties between actors. DND arranges 
these constructs – goals, actions, dependencies and coordination – diagrammatically to depict the structure of a 
network. Figure 2 illustrates the resulting DND for actors within the context of diabetes management in a Canadian 
healthcare system. The DND representation enables technological and organizational designers to assess 
organizational interfaces between interdependent actors, thereby uncovering opportunities to support actors’ goal 
achievement by realigning their information dependencies.  
Whereas the DND illustrates that information flows involving patients are not supported by integrated healthcare 
information systems, for example, the literature suggests several roles for UHIS. For example, patients with chronic 
conditions, such as diabetes, could use pervasive technologies to monitor their blood glucose level, compiling an 
accurate and timely record of their condition, and alerting their primary care physician when conditions are out of 
control (Korhonen and Bardram, 2004). Through interoperability with healthcare providers’ information systems, 
pervasive technologies could enable remote monitoring of patients’ conditions and compliance with treatment plans, 
and alert healthcare providers to intervene and advise as necessary. Nonetheless, investment in a future patient-
centered information system requires significant investment. Therefore, policymakers need to know the significance 
of changes in health outcomes that arise from the application of UHIS in healthcare. For example, in regard to 
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Figure 2, decision makers need to know how significantly improvements in the diagnosis and control of patients’ 
diabetes risks and conditions, made possible by UHIS, would improve patients’ health status over time. To that end, 
we use systems dynamics methodologies in the form of a decision support system (DSS) in support of investment 
decisions by the policymakers.  
 
Figure 2. Dependency Network Diagram within the context of diabetes management  
(adopted from Montazemi et al., 2009) 
 
Whereas policymakers make investment decisions that affect the management of diabetes in a healthcare system, 
both the policymakers and the actors that comprise the system are subject to bounded rationality (e.g., Forrester, 
1961; Simon, 1957). The principle of bounded rationality recognizes that actors rely on simple decision-making 
routines that are subject to serious limitations. Simple routines become increasingly deficient for deciding optimal 
solutions as the numbers of interacting variables in a problem increase, as the pace of change in the environment 
increases, and as more people participate in key decisions. These characteristics constitute dynamic tensions that 
impact on the performance of actors and the systems they comprise. System dynamics (SD) is primarily a diagnostic 
and impact assessment method directed at finding out the effects of policy changes on the performance of systems 
characterized by dynamic tensions (Smits forthcoming; Sterman, 2000). In particular, SD is a suitable method to 
assess the possible impact of a UHIS environment on health outcomes in diabetes management because diabetes 
management meets the four conditions formulated by Smits (Forthcoming). First, because patients’ health status at 
any time is a function of numerous conditions and interactions with healthcare providers, the problem is dynamic, it 
involves a large number of interacting variables, and outcomes cannot be easily foreseen without the help of a 
computer model. Second, the problem is ‘long term’ meaning that effects of a UHIS do not appear immediately but 
only after some period of time. Third, the problem statement includes a ‘reference mode of behavior’, meaning a 
comparison between a new situation (i.e., a patient-centered design) and a current state of behavior. Fourth, the 
problem description gives rise to thinking in terms of flow processes, such as flows of patients through different 
stages of treatment processes.  
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MODEL DEVELOPMENT 
Model Structure Overview 
In this section, we describe the structure of the diabetes model from a system dynamics perspective. Appendix B 
presents the set of variables that comprise the model, and Figure 3 depicts the flow diagram of the model. In this 
model, the complex progression of diabetes has been modeled in four separate stages, normoglycemic, pre-diabetes, 
diabetes, and diabetes with related medical complications. In addition, this model presents the various dynamics 
involved in accelerating or decelerating the intensity of diabetes progression in the population. Population stocks are 
presented in rectangles and double thick arrows with valve symbols indicate flows. Other variables such as 
controlled fraction coefficients directly or indirectly affect the population flows among the stocks. We elaborate on 
the model as follows. 
Population Stocks, Inflows, and Mortalities 
The Canadian population has been divided into seven separate stocks, depicted in Figure 3, that represent distinct 
diabetes statuses within the population: (1) normoglycemic population (i.e. neither having nor particularly at risk for 
diabetes), (2) unidentified and (3) diagnosed pre-diabetics (i.e. at risk with a tendency to experience above-normal 
blood glucose), (4) unidentified and (5) diagnosed diabetics without medical complications (i.e. regularly 
experiencing blood glucose levels above normoglycemic levels), and (6) unidentified and (7) diagnosed diabetics 
with medical complications (i.e. having diabetes as well as diabetes-related medical complications such as stroke, 
heart attack, vision problems and foot disorders) (Agency for Healthcare Research and Quality, 2008; O’Reilly et 
al., 2007). The sum of stocks in the model represents the entire population.  
Stocks are interrelated through flow variables (Sterman, 2000). The population in each of the stocks is determined 
through trade-off between its inflows (e.g., from other stocks) and outflows (e.g., flows to other stocks and 
mortality). Like all flows in the model, population net inflow is expressed as persons per year. The net changes in 
the population and all mortality outflows are modeled to represent net of population inflows to the model based on a 
time series for the Canadian population (cf. http://datafinder.worldbank.org) and published projections of the 
Canadian population until 2050 (Bélanger et al., 2005). 
Mortality rates used for outflows from stocks in the model are functions of (i) a base population mortality rate, (ii) a 
coefficient representing the effect of diabetes stage for each respective stock, and (iii) a coefficient representing the 
population aging effect for each respective stock. The base population mortality rate in Canada is estimated at 
0.763% per year (Bélanger et al., 2005). The non-diabetic (i.e., normoglycemic and pre-diabetes stages) population 
experiences lower mortality rates than the overall population by a coefficient of 1.0/1.2, due to younger-than-
average age of the non-diabetic population (Homer et al., 2004b). We also computed a population aging effect based 
on a time series of the elderly (i.e., age 65-plus) proportion of the Canadian population (Bélanger et al., 2005; 
Statistics Canada, 2007), in which the mortality rate is higher by a coefficient of 8.0 than the population average 
(Homer et al., 2004b). Therefore, the product of base rate, stage and aging effect were applied to the mortality rate 
(outflow) from stocks with normoglycemic and pre-diabetic stages. To account for higher mortality rates for stocks 
in the diabetes stage, a coefficient of 1.4/1.2 was applied (ibid.). Another coefficient of 1.9x8.0 was applied to 
account for the disproportionately higher number of elderly in this stage (ibid.). The base mortality rate for the 
undiagnosed stock in the diabetes stage rises to 12% per year (ibid.). This rate is further adjusted for the diagnosed 
stock in the medical complications stage based on the prorated proportion of patients who have their condition 
controlled (relative mortality risk of 16.7%) or uncontrolled (relative mortality risk of 46.5%) (ibid.). Finally, the 
mortality rate for both stocks in the medical complications stage is also age-adjusted at a coefficient of 7.6x8.0 
(ibid.). Next, we will explain the interrelating flow rates between the stock variables. 
Onset, Progression, and Recovery rates 
Pre-diabetes Onset and Recovery Rates. We assume that pre-diabetes is the precursor to diabetes. Obesity and 
elderly are two factors that substantially change the risk of escalating from normoglycemic to pre-diabetes (Canada 
Safety Council, 2006; Canadian Diabetes Association, 2008a, 2008b; Homer et al., 2004b; Homer et al., 2004c; 
Homer and Hirsch, 2006; Honeycutt et al., 2003; Luo et al., 2007; Wagner et al., 2001). Based on the available data 
for prevalence of pre-diabetes (Homer et al., 2004b), we estimate the average annual onset rate of pre-diabetes for 
the non-elderly and non-obese population as 4.3% per year, and coefficients of 2.6 for obese and 1.15 for elderly 
proportions of the population (ibid.) based on time series for obesity (Le-Petit, 2005; Luo et al., 2007; Tjepkema, 
2004, 2006) and elderly (Bélanger et al., 2005; George et al., 2001; Statistics Canada, 2007) population 
composition. Recovery from pre-diabetes stage is affected by the changes in patients’ diets and lifestyles that bring  
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Figure 3. Dynamic model of diabetes 
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diabetes conditions and risk factors under control (O’Reilly et al., 2007). We estimate the normal rate of recovery from pre-
diabetes as 10%, with a coefficient of 1.5 for the prorated portion of diagnosed pre-diabetics that have their condition and 
risks under control, and 50% of any reductions in the incidence of obesity is added to the recovery rate (Homer et al., 2004b). 
Diabetes Onset Rates. One onset (flow) rate is calculated for the progression of the undiagnosed pre-diabetes population to 
the diabetic stage, and another for diagnosed pre-diabetes patients. Both rates are affected by obesity and age. The average 
annual onset rate of diabetes for non-elderly and non-obese population is estimated at 1.35% per year, with a coefficient of 
2.6 for obese and 1.52 for elderly proportions of the population (Homer et al., 2004b) based on time series of obesity and 
elderly as previously discussed. For the proportion of pre-diabetics that have their risk factors under control, the risk of 
developing diabetes conditions is reduced to 58% (Homer et al., 2004b).  
Onset Rates of Medical Complications Related to Diabetes. One onset (flow) rate is calculated for the progression of the 
undiagnosed diabetics population to the medical complications stage, and another for diagnosed diabetics. Both rates are 
affected by obesity and age. The base onset rate for undiagnosed diabetics is estimated at 7.9% per year. The same rate is 
assumed for diagnosed diabetics who don’t have their chronic disease under control. However for diagnosed diabetics who 
have their chronic disease under control the rate is reduced to 16% (Homer et al., 2004b). 
Diagnosis rates 
Pre-diabetes Diagnosis Rate. The “unidentified pre-diabetes” stock and “diagnosed pre-diabetes” stock are interrelated 
through flow variable “pre-diabetes diagnosis”. Pre-diabetes diagnosis flow is the annual rate at which persons with 
unidentified pre-diabetes are diagnosed and brought under providers’ care. The calculation involves a first-order delay 
(Sterman, 2000) of the pre-diabetes onset flow, with an average delay time equal to 1.5 years, reflecting the median of the 
typical range of detection (0-3 years) (Homer et al., 2004b). The calculation next subtracts those who have died (i.e., 
mortality outflows from the stock) or progressed to another stage during the delay. Finally, it applies the prevailing diagnosis 
fraction for pre-diabetes. The fraction is the product of the fraction of screenings for pre-diabetes and the average sensitivity 
of the screening test used for pre-diabetes, estimated at coefficients of 0.30 and 0.84 respectively (Genuth et al., 2003; Homer 
et al., 2004b). 
Diabetes Diagnosis Rate. The “unidentified diabetes” stock and “diagnosed diabetes” stock are interrelated through flow 
variable “diabetes diagnosis” in a similar fashion. Diabetes diagnosis flow is the annual rate at which persons with 
unidentified diabetes are diagnosed and brought under diabetes care. The diagnosis typically occurs as the result of screening 
the population with significant risk factors for diabetes. The calculation involves a first-order delay of diabetes onset flow for 
1.5 years and subtractions of outflows that occur during the delay, as described in the previous stage, with only the diagnosis 
fraction changing to reflect screened diabetics (coefficient 0.86, cf. Homer et al., 2004b) and sensitivity of screenings specific 
to diabetics (coefficient 0.60x0.97 + 0.40x0.84). The latter coefficient is estimated based on 60% receiving the more 
conclusive oral glucose tolerance test (OGTT), which has 97% sensitivity, and the remainder receiving only the fasting 
plasma glucose test (FPGT), which has a sensitivity of 84% (Harris, 1995; Homer et al., 2004b). 
Medical Complications Diagnosis Rate. The “unidentified medical complications” stock and “diagnosed medical 
complications” stock are interrelated through flow variable “complications diagnosis” in a similar fashion. Complications 
diagnosis flow is the annual rate at which diabetics who have developed diabetes-related medical complications are 
diagnosed and brought under providers’ care. The diagnosis typically occurs as the result of a physician visit or emergency 
pertaining to symptoms of medical complications. Because symptoms are more visible, an estimated average of 1.0 years is 
used for the first-order delay at this stage. Outflows that occur during the delay are subtracted, as described in the previous 
stages. The diagnosis fraction is a function of the fraction of this population who have ready access to healthcare (86%), the 
fraction with symptoms severe enough to cause them to seek medical attention (33%), a high proportion receiving OGTT in 
response to more apparent symptoms (90% proportion x 97% sensitivity) and the remainder receiving FPGT (10% proportion 
x 84% sensitivity) (Harris, 1995; Homer et al., 2004b). 
Pre-diabetes and Diabetes Control Fractions 
Patients’ control of blood glucose, blood pressure and lipids is considered critical for reducing the incidence of progression 
from pre-diabetes to diabetes, developments of medical complications due to diabetes, and mortalities from medical 
complications (Skyler, 2004). Because a diagnosed patient whose conditions and risk factors are not under control is not that 
different from undiagnosed persons, it is important to identify the fraction that are and are not under control (Homer et al., 
2004b). For the population of diagnosed pre-diabetics, the controlled fraction is formulated as the product of two factors: (1) 
the fraction of hyperglycemic population (people with pre-diabetes) under proper clinical management, and (2) the fraction of 
those patients who maintain control of their conditions and risk factors. The latter is the output of three contributing factors: 
(1) the ability to self-monitor one’s condition and report any changes to one’s healthcare providers, (2) the ability to adopt a 
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healthy lifestyle favorable for the maintenance of control, and (3) the ability to afford prescribed medications needed for 
maintaining control. Based on this, we can frame the equation for calculating the controlled fraction of pre-diabetics as 
follows: 
“Controlled fraction of managed diabetes population = 
(1-Fraction of hyperglycemics who need medications for control)  Ability to adopt healthy lifestyle 
+ 
Fraction of pre-diabetics who need medications for control  Ability to self monitor  (1 - Fraction of 
Hyperglycemics who need lifestyle change for control if taking medications + Fraction of 
Hyperglycemics who need lifestyle change for control if taking medications  Ability to adopt healthy 
lifestyle)”. 
 
The first part of the equation represents conditions for pre-diabetics who control their diabetes risk factors by adopting a 
healthy life style and diet, estimated at 60%, and a fraction of pre-diabetics that require medications, estimated at 33% 
(Homer et al., 2004b). The second part of the equation represents the ability of the latter medication-dependent pre-diabetics 
to self-monitor their medication requirements, estimated at 84%, and the ability of those who require both medication and 
lifestyle changes, estimated at 33%. The same formula and coefficients apply to diagnosed diabetics and to diabetics 
diagnosed with medical complications, with the sole exception that the fraction of patients that are medication-dependent 
rises to 95% (Homer et al., 2004b).  
MODEL VALIDATION 
The stated model simulates the Canadian population life cycles (i.e., flows) through the stages of diabetes based on the 
effects of diabetes management factors in Canada as-is. We assume a year as the unit of time. We set all stocks to start from 
their corresponding values in 1950, the year in which our simulation commences.  
Simulation models are validated by comparing the simulated behavior and outputs of the model to the actual behavior of the 
system in the real world (Sterman, 2000). To this end, we compare the simulated population of Canada from 1950 to 2009 to 
actual published data (cf. http://datafinder.worldbank.org) and from 2010 to 2050 are based on published projections 
(Bélanger et al., 2005; George et al., 2001). Testing the differences between the two sets of data using paired t-test showed 
no significant difference (t=0.265, p>0.05) 
We also performed a statistical comparison between published reports of diabetes incidence in the Canadian population 
throughout the 1990s (Public Health Agency of Canada, 1999) and data from our simulation. A two-tailed comparison of the 
means shows that data from the simulation do not vary significantly from the published data (t=2.45, p>0.05). Therefore, the 
simulation exhibits an acceptable match to the actual behaviors of the system. 
DEFINING SCENARIOS 
Our basic assumption is that a UHIS that helps to “detect disease early and support compliance with commonly accepted care 
plans” (Dishman, 2004, p. 35) will mitigate patients’ health deterioration and mortality due to the escalation of diabetes (i.e., 
maintaining better health status) by improving diagnoses and control of patients’ risk factors and conditions (ADA, 2003; 
Testa and Simonson, 1998; Wagner et al., 2001). Because our focus in this paper is on improving diagnosis and control for 
pre-diabetic and diabetic patients, we will not simulate manipulations to the general (i.e., normoglycemic) population. In 
accordance with our patient-centered focus, we model the two effects of (i) improved diagnosis, and (ii) improved control 
rates on the incidences of pre-diabetes, diabetes, medical complications and mortality in the population over time. These two 
effects are modeled as four scenarios: (#1) as-is (i.e., status quo, 0% improvement), (#2) 5% improvements in diagnosis and 
control rates, (#3) 10% improvements in diagnosis and control rates, and (#4) 20% improvements in diagnosis and control 
rates.  
The improvements are modeled using “step” variables in the simulation (Sterman, 2000). That is, step variables with the 
improvements corresponding to each respective scenario are added to the diagnosis and control rates for pre-diabetes, 
diabetes, and medical complications stages starting in year 2008 of the simulation run. The step variables are listed in 
Appendix A and elaborated as follows. Specifically, for scenario #2, we increased “step variable for stage 1 diagnosis rate”, 
“step variable for stage 2 diagnosis rate”, “step variable for stage 3 diagnosis rate”, and “step variable for effective controlled 
fraction of patients” by 5%. For scenario #3, we increased “step variable for stage 1 diagnosis rate”, “step variable for stage 2 
diagnosis rate”, “step variable for stage 3 diagnosis rate”, and “step variable for effective controlled fraction of patients” by 
10% each. For scenario #4, we increased “step variable for stage 1 diagnosis rate”, “step variable for stage 2 diagnosis rate”, 
“step variable for stage 3 diagnosis rate”, and “step variable for effective controlled fraction of patients” by 20% each. 
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To analyze the effects on patients in the population throughout their life cycle, we ran each scenario from 1950 to 2050, an 
end date that approximates the average life cycle of Canadians today assuming a life expectancy of 82 years and an average 
population age of 45 (Bélanger et al., 2005). We expect the incidence of diabetes, diabetes-related complications and 
mortality in the population to decrease with improvements in diagnosis and control rates.  
RESULTS 
For each of the four scenarios, the projected population and incidences of pre-diabetes, diabetes, diabetes-related medical 
complications and mortality as at 2050 are summarized in Table 1, and year over year changes are depicted in Figures 4 to 7 
respectively. Results from simulation under the “status quo” scenario project that within the lifespan of the average Canadian 
today (i.e., 2008-2050) the Canadian population will grow to 42,204,300 people of which 13.421,660 will be pre-diabetic, 
2,891,860 will have escalated to diabetes, 580,697 will have diabetes and related medical complications, and a cumulated 
21,169,955 mortalities will have occurred.  
Under the scenario of 5% improvement in diagnosis and control rates, the incidence of pre-diabetes, diabetes, diabetes-related 
medical complications and mortality would be 13,197,730, 2,860,000, 568,163 and 21,012,018 respectively within a 
population of 42,356,800 people. These results represent net benefits of 223,930 fewer pre-diabetics, 31,860 fewer diabetics, 
12,534 fewer people escalating to diabetes and related medical complications, and a cumulated 157,937 fewer mortalities 
versus status quo. 
Under the scenario of 10% improvement in diagnosis and control rates, the incidence of pre-diabetes, diabetes, diabetes-
related medical complications and mortality would be 12,952,310, 2,823,668, 553,707 and 20,843,106 respectively within a 
population of 42,519,700 people. These results represent net benefits of 469,350 fewer pre-diabetics, 68,192 fewer diabetics, 
26,990 fewer people escalating to diabetes and related medical complications, and a cumulated 326,849 fewer mortalities 
versus status quo. 
Under the scenario of 20% improvement in diagnosis and control rates, the incidence of pre-diabetes, diabetes, diabetes-
related medical complications and mortality would be 12,397,440, 2,736,289, 519,448, and 20,475,574 respectively within a 
population of 42,874,100 people. These results represent net benefits of 1,024,220 fewer pre-diabetics, 155,571 fewer 
diabetics, 61,249 fewer people escalating to diabetes-related medical complications, and a cumulated 694,381 fewer 
mortalities versus status quo. 
Projected populations: 
Scenario Total 
Pre-
Diabetic Diabetic 
Medical 
Complications 
Mortalities 
(cumulated) 
(#1) Status Quo 42,204,300 13.421,660 2,891,860 580,697 21,169,955 
(#2) 5% 
Improvement 
42,356,800 13,197,730 2,860,000 568,163 21,012,018 
(#3) 10% 
Improvement 
42,519,700 12,952,310 2,823,668 553,707 20,843,106 
(#4) 20% 
Improvement 
42,874,100 12,397,440 2,736,289 519,448 20,475,574 
Table 1. Projected populations by scenario as at the year 2050 
The results also show that doubling the improvements in diagnosis and control (i.e., from 5% to 10%, or 10% to 20%) more 
than doubles the beneficial effects over patients’ life cycles. Based on these results, we conclude that ubiquitous healthcare 
information systems that enable better-informed decision-making that improves diagnosis and control of diabetes risks and 
conditions can be expected to significantly reduce the incidence of pre-diabetes, diabetes and diabetes-related medical 
complications in the population over the course of patients’ life cycles, and significantly reduce the number of mortalities. 
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Figure 4. Reduction in annual incidence of pre-diabetes  Figure 5. Reduction in annual incidence of diabetes  
  
Figure 6. Reduction in annual incidence of diabetes-related medical complications Figure 7. Cumulative reductions in mortalities  
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CONCLUDING REMARKS 
The overarching objective of diabetes management is to mitigate the escalation of patients’ conditions and risk 
factors over time. Diabetes management depends on the participation of patients and the advice of healthcare 
providers. Consequently, care decisions and treatment depend on the exchange of all information relevant to care 
decisions among patients and healthcare providers (Bugge et al., 2006). To that end, the literature has advocated the 
use of UHIS (Korhonen and Bardram, 2004) to help detect medical conditions early and support patients’ 
compliance with treatment plans (Dishman, 2004). However, the significance of patients’ health status 
improvements that would arise from better-informed detection (i.e., diagnosis) and greater compliance is unknown. 
Our system dynamics model enables policy-makers to assess the impact of UHIS on improved health status of the 
patients. 
There are a number of limitations enforced in this study.  This paper presents a limited number of “what if” 
scenarios (i.e., 5%, 10%, and 20% improvements), applied only to diagnosis and control rates for pre-diabetics and 
diabetics. The results presented here do not reflect possible improvements to prevention and obesity – a major factor 
in the escalation of diabetes in the population – in the normoglycemic population that could conceivably result from 
UHIS that prompts individuals to increase their exercise for instance (e.g., Korhonen and Bardram, 2004). The 
results do not illustrate the effects of earlier diagnosis (i.e., we improved the proportion or rate of successful 
diagnoses while retaining the “as-is” time lag for diagnosis) that could conceivably result from healthcare providers 
being alerted by real-time monitoring of patients’ biological conditions or identifying at-risk individuals with the aid 
of data mining systems (e.g., Bonato, 2003). The results do not reflect potential operational benefits that could 
conceivably arise from automated data gathering of patients’ biological conditions, real-time alerts that enable 
proactive rather than reactive responses to emergencies such as cardiovascular events, and more efficient decision-
support made possible by data mining systems that analyze UHIS data (e.g., Bonato, 2003). Nor do the results 
reflect potential benefits with respect to other diseases that could conceivably arise from better compliance with 
practices, such as increased exercise, as a result of UHIS.  
Nonetheless, we find that improved diagnosis and control afforded by UHIS has the potential to provide (i) a 
significant improvement in patients’ health status arising from significantly less deterioration of health throughout 
patients’ life cycles, and (ii) a significant reduction of mortalities. Therefore, the health status improvements 
presented in this paper should be interpreted as the minimum benefits that decision-makers may expect from better-
informed decisions and improved diagnosis and control made possible through the application of UHIS in support of 
a patient-centered care approach to diabetes management. Future research can expand our model to include the 
following enhancements: (1) potential benefits of improved preventative care afforded by pervasive consumer 
technologies that monitor factors such as diet, exercise and obesity, (2) the effects of earlier diagnoses, and (3) 
operational efficiencies that could result from patient-centered information systems, such as automated 
recordkeeping and real-time diagnoses. 
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APPENDIX A – VARIABLES USED IN MODEL 
Variable Name Definition 
Stock Variables 
Canadian Normoglycemic 
Population Canadian population with normal level of blood sugar 
Unidentified Population of 
Stage 1 Patients 
Canadian population with pre-diabetes indications who have NOT 
been diagnosed, yet. 
Diagnosed Population of Stage 
1 Patients 
Canadian population with pre-diabetes indications who have been 
diagnosed with pre-diabetes indications. 
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Unidentified Population of 
Stage 2 Patients 
Canadian population with diabetes without complications whose 
chronic disease have NOT been diagnosed, yet. 
Diagnosed Population of Stage 
2 Patients 
Canadian population with diabetes without complications whose 
chronic illness have been diagnosed. 
Unidentified Population of 
Stage 3 Patients 
Canadian diabetics with medical complications whose chronic 
disease have NOT been diagnosed, yet. 
Diagnosed Population of Stage 
3 Patients 
Canadian diabetics with medical complications whose chronic 
disease have been diagnosed. 
Flow Variables 
Population Inflow Yearly-based net increase in Canadian population (excluding the 
effect of death). 
Normoglycemic death rate Yearly-based death rate of population with normal blood sugar level. 
Onset rate for pre-diabetes 
Yearly-based rate of pre-diabetes onset for normoglycemic 
population (from normoglycemic stage to unidentified pre-diabetes 
stage). 
Recovery from unidentified 
stage 1 
Yearly-based rate at which unidentified pre-diabetics are recovered 
(i.e. become normoglycemic). 
Unidentified stage 1 death rate Yearly-based death rate of pre-diabetics (i.e. as pre-diabetes doesn’t 
affect the patient’s death, it is equal to normoglycemic death rate). 
Progression rate from 
unidentified stage 1 to 
unidentified stage 2 
Yearly-based rate at which unidentified pre-diabetics’ illness is 
progressed to chronic diabetes (i.e. stage 2) which is not diagnosed. 
Diagnosis rate for stage 1 
patients 
Yearly-based rate at which the unidentified pre-diabetics are 
diagnosed as having pre-diabetes. 
Recovery from diagnosed stage 
1 
Yearly-based rate at which pre-diabetics whose illness is diagnosed 
are recovered (i.e. become normoglycemic). 
Diagnosed stage 1 death rate Yearly-based death rate of pre-diabetics (i.e. as pre-diabetes doesn’t 
affect the patient’s death, it is equal to normoglycemic death rate). 
Progression rate from diagnosed 
stage 1 to diagnosed stage 2 
Yearly-based rate at which diagnosed pre-diabetics’ illness is 
progressed to chronic diabetes (i.e. stage 2) and this progression is 
also diagnosed. 
Unidentified stage 2 death rate Yearly-based death rate of unidentified diabetics without medical 
complications. 
Progression rate from 
unidentified stage 2 to 
unidentified stage 3 
Yearly-based rate at which unidentified diabetics’ illness (i.e. 
without medical complications) is progressed to diabetes with 
medical complications and this progression is not diagnosed. 
Diagnosis rate for stage 2 
patients 
Yearly-based rate at which the unidentified diabetics without 
medical complications are diagnosed. 
Diagnosed stage 2 death rate Yearly-based death rate of diagnosed diabetics without medical 
complications. 
Progression rate from diagnosed Yearly-based rate at which diagnosed diabetics’ illness (i.e. without 
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stage 2 to diagnosed stage 3 medical complications) is progressed to diabetes with medical 
complications and this progression is also diagnosed. 
Death rate for Unidentified 
stage 3 patients 
Yearly-based death rate of unidentified diabetics with medical 
complications. 
Diagnosis rate for stage 3 
patients 
Yearly-based rate at which the unidentified diabetics with medical 
complications are diagnosed. 
Death rate for diagnosed stage 3 
patients 
Yearly-based death rate of diagnosed diabetics with medical 
complications. 
Auxiliary Variables 
Population death rate Time series of Canadian population death rate from 1950 to 2050. 
Net population growth Yearly-based net difference in the number of Canadian population. 
Obese Fraction Time series of fraction of obese population in Canada from 1950 to 2050. 
Elderly portion Time series of portion of elderly population (+65) in Canada from 1950 to 2050. 
Ave. time from S1 onset to 
detection for undx 
hypreglycemic 
Average time from symptoms onset for an unidentified pre-diabetic 
to when she is diagnosed by the medical doctor. 
Dx fraction of recent undx S1 
onset 
The fraction of unidentified pre-diabetics who are diagnosed, each 
year. 
Ave. time from S2 incidence to 
detection for undx 
hypreglycemic 
Average time from symptoms onset for an unidentified diabetic 
without medical complications to when she is diagnosed by the 
medical doctor. 
Dx fraction of recent undx S2 
onset 
The fraction of unidentified diabetics without medical 
complications who are diagnosed with the disease, each year. 
Ave. time from S3 incidence to 
detection for undx 
hypreglycemic 
Average time from symptoms onset for an unidentified diabetic 
with medical complications to when she is diagnosed by the 
medical doctor. 
Dx fraction of recent undx S3 
onset 
The fraction of unidentified diabetics with medical complications 
who are diagnosed with the disease, each year. 
Fraction of diagnosed receiving 
effective care 
Fraction of patients with diagnosed illness who are receiving 
effective care (i.e. effective in decreasing the progression of the 
disease) based on: 1) Their ability to adopt a healthy lifestyle, 2) 
Their ability to self-monitor themselves, and 3) their ability to 
afford the required medications. 
Controlled fraction coefficient 
for S1 
Fraction of diagnosed pre-diabetics whose health problem is 
controlled (i.e. its progression is delayed or stopped). 
Controlled fraction coefficient 
for S2 and S3 
Fraction of diagnosed diabetics whose health problem is controlled 
(i.e. its progression is delayed or stopped). 
Auxiliary Variables for Manipulation (“Step Variables”) 
Step variable for stage1 Step variable for inducing the improvements to the diagnosis rate of 
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diagnosis rate unidentified pre-diabetics (i.e. Stage 1). 
Step variable for stage2 
diagnosis rate 
Step variable for inducing the improvements to the diagnosis rate of 
unidentified diabetics without medical complications (i.e. Stage 2). 
Step variable for stage3 
diagnosis rate 
Step variable for inducing the improvements to the diagnosis rate of 
unidentified diabetics with medical complications (i.e. Stage 3). 
Step variable for Effective 
Controlled Fraction of patients 
Step variable for inducing the improvements to the control rate for 
diagnosed patients (i.e. for controlled fraction of diagnosed patients 
in all stages). 
Table 2. Simulation variables and their definitions, adapted from Homer et al., (2004b) 
 
 
